Determinan pola resistensi pasien Multi-Drug Resistant Tuberculosis (MDRTB) : Studi Multi-Center di Jember, Indonesia

Intan Wahidah, Khoiriyatul Muhlishoh Arwi, Ika Norcahyanti, Ema Rachmawati, Ika Puspita Dewi, Dhita Evi Aryani, Afifah Machlaurin

Abstract


Drug-resistant, particularly multidrug resistance tuberculosis (MDRTB), is an emerging problem due to its low success rate of treatment outcomes. Most MDRTB in Indonesia was rifampicin resistant (RRTB). There is a paucity of evidence on the determinants of the MDRTB types. This study aims to assess the determinant of resistance type. A hospital-based cross-sectional study was conducted in two referral hospitals for MDRTB in the city of Jember Indonesia. MDRTB patients registered in the web-based information system tuberculosis in Indonesia (SITB) from 2018 to 2022 who had a complete medical record were included. Multi-variate logistic regression analysis was done to identify determinants of MDRTB type. Odds ratios (ORs) with 95% confidence intervals (CIs) were computed. From 347 patients, there were 186 patients excluded due to un-completeness of the records. In total 158 patients were included. Most patients (53,8%) were encountered rifampicin resistance (RR-TB), followed by MDRTB (37,3%), Pre-XDR TB (6,96%), and XDR-TB (1,90%). The sociodemographic variable such as age, gender, residence, and comorbid were not significantly correlate with the type of MDRTB.  The only determinant affects the type of MDR/PreXDR/XDR TB was the previous history of TB treatment (OR = 2,4 kali (95% CI: 1,2 - 4,7)). This study showed that patients with the history of TB treatment are more likely to encountered more severe types of TB resistance such as MDRTB/PreXDR/XDR-TB. Therefore, health-care workers should prioritize the adherence of TB treatment especially in patients with previous history of TB treatment.

Keywords


Multi-drug resistance; Tuberculosis; determinants

Full Text:

PDF

References


WHO. Global Tuberculosis Report. WHO, editor. Geneva: World Health Organization; 2022.

Kementerian Kesehatan RI. Laporan Program Penanggulangan Tuberkulosis Tahun 2021. Jakarta: Kementerian Kesehatan RI; 2022.

Damayanti L, Widada W, Adi S. Status Pengobatan Berhubungan Dengan Kejadian Tuberkulosis Resistan Obat Pada Usia Produktif. Prof Heal J. 2022;03:138-48.

Kementerian Kesehatan RI. Penanggulangan Tuberkulosis. Kementeri Kesehat Republik Indones. Indonesia; 2016;

Kementerian Kesehatan RI. Workshop Virtual Penggunaan Aplikasi Sistem Informasi Tuberkulosis (SITB) bagi Petugas Pencatatan dan Pelaporan TBC UPT Pemasyarakatan Seluruh Indonesia - TBC Indonesia. Kementeri. Kesehat. RI. 2020.

Sihombing H, Sembiring H, Amir Z, Sinaga BY. Pola Resistensi Primer pada Penderita TB Paru Kategori I di RSUP H. Adam Malik, Medan. J Respir Indo. 2012;32:138-83.

Nikmawati A, Windarwati W, Hardjoeno H. Resistensi Mycobacterium Tuberculosis Terhadap Obat Anti Tuberkulosis. Indones J Clin Pathol Med Lab. 2018;12:58.

Adiwinata R, Rasidi J, Marpaung M. Profil Klinis dan Evaluasi Pengobatan Pasien Rifampicin- Resistant dan Multidrug-Resistant Tuberculosis di RSUD Dr. Kanujoso Djatiwibowo Balikpapan. J Respir Indo. 2018;38:135-42.

Yuwono AR, Artanti LO, Amal S. PROFIL KASUS TUBERKULOSIS RESISTEN OBAT DI RSUP Dr. SOERADJI TIRTONEGORO KLATEN PERIODE TAHUN 2012-2017. Pharm J Islam Pharm. 2018;2:01.

Syahrezki M. Faktor Risiko Tuberkulosis Multidrug Resistant ( TB-MDR ). J Agromed Unila. 2015;2:413-8.

Bawonte TG, Mambo CD, Masengi ASR. Faktor-Faktor Yang Mempengaruhi Tuberculosis Multidrug Resistance ( TB MDR ). 2021;9:117-25.

Putri VA, Yovi I, Fauzia D. Profil Pasien Tuberculosis Multidrug Resistance (TB-MDR) di Poliklinik TB-MDR RSUD Arifin Achmad Provinsi Riau Periode April 2013-Juni 2014. J Online Mhs Fak Kedokt. 2015;1:1-17.

Kementerian Kesehatan RI. Profil Kesehatan Indonesia Tahun 2017. Jakarta: Kementerian Kesehatan RI; 2018.

Triandari D, Ratna S, Administrasi R, Kesehatan K, Ilmu J, Masyarakat K. Kejadian Tuberkulosis Multi Drug Resistant di RSUP dr. Kariadi. HIGEIA (Journal Public Heal Res Dev. Department of Drama, Dance and Music, Semarang State University; 2018;2:194-204.

Sinaga BYM. Karakteristik Penderita Multidrug Resistant Tuberculosis yang Mengikuti Programmatic Management of Drug-Resistant Tuberculosis di Rumah Sakit Umum Pusat H. Adam Malik Medan. 2013;

Nur A, Sukartini T, Harmayetty. Karakteristik Pasien Multidrug Resistant Tuberculosis (MDR-TB) di RSUD Makassar. J Penelit Kesehat Suara Forikes. 2019;10:253-6.

Bijawati E, Amansyah M, Nurbiah. FAKTOR RISIKO PENGOBATAN PASIEN MULTIDRUG RESISTANCE TUBERCULOSIS (MDR-TB) DI RSUD LABUANG BAJI KOTA MAKASSAR TAHUN 2017. J Nas Ilmu Kesehat. 2018;1:1-17.

Nasarudin J, Zn AU, Karjadi TH, Rumende CM. Prevalensi Kejadian Resistensi Rifampisin pada Pasien TB-HIV dan Faktor-Faktor yang Mempengaruhi. 2015;3.

Rizal VP, Rustam E, Anggrainy F. Karakteristik Pasien Multidrug Resistant Tuberculosis yang Dirawat di Bangsal Paru RSUP Dr. M. Djamil Padang Periode 2018 - 2020. J Farm Higea. 2021;13.

Ainiyah SN, Soedarsono, Umiastuti P. Hubungan Peran Keluarga dan Kepatuhan Pasien TB MDR di RSUD Dr. Soetomo Surabaya. J Respirasi. 2019;5:1-4.

Asmalina, Siagian P, Yunita R, Amir Z, Nasution TA. Kejadian Tuberkulosis Resistensi Primer pada Fasilitas Pelayanan Kesehatan Primary Resistence Tuberculosis Cases in Health Care Facility. J Respir Indo. 2016;36:100-5.

Widiati B, Majdi M. Analisis Faktor Umur, Tingkat Pendidikan, Pekerjaan, Dan Tuberkulosis Paru Di Wilayah Kerja Puskesmas Korleko, Kabupaten Lombok Timur. J Sanitasi dan Lingkung. 2021;2:173-84.

Nurdin N. Analisis faktor - faktor Risiko Individu terhadap Tuberculosis Multidrug Resistant (TB MDR) di Provinsi Sumatera Selatan. J Kesehat Komunitas. 2020;6:63-7.

Janan M. Faktor-faktor risiko yang berhubungan dengan peningkatan prevalensi kejadian tb mdr di kabupaten brebes tahun 2011-2017. J Kebijak Kesehat Indones. 2019;8:64-70.

PERKENI PEI. Pengelolaan Dan Pencegahan Diabetes Melitus Tipe 2 Dewasa di Indonesia. PB Perkeni. PB PERKENI; 2019.

Aziz KK. Pengobatan Tuberkulosis Paru dan Diabetes Melitus serta Pengaruhnya terhadap Risiko Multi-Drug Resistant Tuberculosis (MDR-TB). Anat Med J Fak Kedokt Univ Muhammadiyah Sumatera Utara. 2019;2:22-32.

Nugrahaeni DK, Malik US. ANALISIS PENYEBAB RESISTENSI OBAT ANTI TUBERKULOSIS. J Kesehat Masy. 2015;11:8-15.

Nurmala QP, Habib I, Nugroho H. Hubungan Riwayat Pengobatan Tuberkulosis dengan Insidensi Multidrugs Resistant Tuberculosis ( MDR TB ). Dep Med Educ. Yogyakarta; 2019;38.

Aini ZM, Rufia NM. Karakteristik Penderita Tuberculosis Multidrug Resistant (TB MDR) di Sulawesi Tenggara Tahun 2014-2017. Medula. 2019;6:547-57.

Soedarsono S, Mertaniasih N, Hasan H, Kusmiati T, Permatasari A, Kusumaningrum D, et al. Line probe assay test in new cases of tuberculosis with rifampicin resistance not detected by Xpert MTB/RIF. Int J Mycobacteriology. Wolters Kluwer Medknow Publications; 2022;11:429-34.

Sirait N, Parwati I, Dewi NS, Suraya N. Validitas Metode Polymerase Chain Reaction GeneXpert MTB / RIF pada Bahan Pemeriksaan Sputum untuk Mendiagnosis Multidrug Resistant Tuberculosis Validity of Polymerase Chain Reaction GeneXpert MTB / RIF Method on Sputum Sample Examination to Diagnose Mult. Bandung Med J. 2013;45:234-9.

Imam MDA, Fatima N, Shameem M, Ahmed S. Evaluation of the GeneXpert Mycobacterium tuberculosis/Rifampicin Assay for Early Detection of Extrapulmonary Tuberculosis and Rifampicin Resistance in Aligarh Region of Northern India. CHRISMED J Heal Res. 2023;10:44-9.

Wibowo A, Burhan E, Putra AC. Pola Resistansi Kuman Tuberkulosis dan Regimen Pengobatan Pada Pasien Tuberkulosis Resisten Obat Di Rumah Sakit Pusat Rujukan Respirasi Nasional Persahabatan Jakarta. J Kedokt Univ Lampung. 2021;5:1.

Papich MG. Fluoroquinolone Antimicrobial Drugs | Veterian Key. Fastest Vet. Med. Insight Engine. 2018.

Imam FRS, Umboh JML, Tuda JSB. Faktor-faktor Risiko yang Berhubungan dengan Kejadian Multidrug-Resistant Tuberculosis (TB-MDR) di Kota Ternate, Maluku Utara. e-CliniC. 2023;11:260-8.




DOI: https://doi.org/10.37311/ijpe.v4i1.24636

Refbacks

  • There are currently no refbacks.


Copyright (c) 2024 Afifah Machlaurin, Intan Wahidah, Khoiriyatul Muhlishoh Arwi, Ika Norcahyanti, Ema Rachmawati, Ika Puspita Dewi, Dhita Evi Aryani

Creative Commons License
Indonesian Journal of Pharmaceutical Education is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.